<DOC>
	<DOC>NCT01098162</DOC>
	<brief_summary>The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®. The observed population will be only patients with one baseline antiepileptic drug. Seizure control and tolerability data will be evaluated.</brief_summary>
	<brief_title>Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>The patient's treatment must be in accordance with the local marketing authorization (MA) for Vimpat® The decision to prescribe Vimpat® has to be made by the physician before and independently of his/her decision to include the patient in the study The Vimpat® treatment should have been started not longer than 2 weeks before study inclusion of the patient The patient must have a diagnosis of Epilepsy with PartialOnset Seizures Based on the physician's clinical judgment, the patient's seizure activity is not controlled sufficiently on a current monotherapy and it is in the patient's best interest to be prescribed adjunctive Vimpat® In accordance with the Summary of Product Characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat®</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial-Onset Seizures</keyword>
	<keyword>Adjunctive therapy</keyword>
</DOC>